Resource data sheet
DNA Bank Top
Please review the QC test results indicated by check icon below as well as clone information before placing your order.

pCGT-PDGFRA-C (#RDB15465)

Expression vector of human PDGFRA (deletion mutant with only the C-terminal portion), T7-tag.

Clone info. Expression vector of human PDGFRA (deletion mutant with only the C-terminal portion), tagged with T7 at N-terminal.
Comment Expression was confirmed by the depositor with immunostaining.
Vector backbone pCGT (plasmid)
Selectable markers Amp^r
Gene/insert name human PDGFRA cDNA
Depositor|Developer Kondo, Takeshi |
 
Sequence (full) RDB15465zzt01.seq compiled by us

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.
Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link] For for-profit-research purpose, please contact us. 
Terms and conditions for distribution In publishing the research results obtained by use of the BIOLOGICAL RESOURCE, a citation of literature designated by the DEPOSITOR is requested (Ibata, M et al. Cancer Sci. 108 (2), 200-207, 2017). The availability of the BIOLOGICAL RESOURCE is limited to a RECIPIENT of a not-for profit institution for a not-for-profit academic purpose.
提供案内 (日本国内) [open/close]

必要書類
提供依頼書  [依頼書の記入例 ]
提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ]
手続きの概要は、「提供申込みについて[link]」をご覧ください。営利目的利用についてはお問い合わせください。
MTAに書く使用条件 利用者は、研究成果の公表にあたって寄託者の指定する文献を引用する（Ibata, M et al. Cancer Sci. 108 (2), 200-207, 2017）。本件研究材料は、非営利機関の非営利学術研究に限って提供する。

Catalog # Resource name Shipping form Fee (non-profit org.)
RDB15465 pCGT-PDGFRA-C DNA solution JPY 9,460 (not-for-profit academic purpose)
plus cost of shipping containers, dry ice (if required) and shipping charge

Please review the QC test results indicated by check icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pCGT-PDGFRA-C was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB15465).

Reference section:

Ibata, M., Iwasaki, J., Fujioka, Y., Nakagawa, K., Darmanin, S., Onozawa, M., Hashimoto, D., Ohba, Y., Hatakeyama, S., Teshima, T., Kondo, T., Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. Cancer Sci. 108 (2): 200-207 (2017). PMID 27960034. [link to RRC of NBRP]

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet RDB15465_B2Cgp1-1.pdf check

Nucleotide sequence of a portion of this resource (if available).

Primer: CMV_Forward (Pr0016)
Region: CMV pro, HSV TK 5'-UTR, insert (FL) 5'
Sequence file: RDB15465_B2Cga.seq check
>D04855B3_B2Cg_1_CMV_Forward_A11_02_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNCCN NNNNNNNNNN ATGGGCGGTA GGCGTGTACG GTGGGAGGTC
   61 TATATAAGCA GAGCTCGTTT AGTGAACCGT CAGATCGCCT GGAGACGCCA TCCACGCTGT
  121 TTTGACCTCC ATAGAAGACA CCGGGACCGA TCCAGCCTCC GGGGGATCTT GGTGGCGTGA
  181 AACTCCCGCA CCTCTTCGGC CAGCGCCTTG TAGAAGCGCG TATGGCTTCT AGGATGGCAT
  241 CGATGACAGG TGGCCAACAG ATGGGTTCTA GGATGGCATC GATGACAGGT GGCCAACAGA
  301 TGGGTTCTAG AGGATCTACT AGTCATATGG ATTGGTCTAG ACTGCCATAT GACTCAAGAT
  361 GGGAGTTTCC AAGAGATGGA CTAGTGCTTG GTCGGGTCTT GGGGTCTGGA GCGTTTGGGA
  421 AGGTGGTTGA AGGAACAGCC TATGGATTAA GCCGGTCCCA ACCTGTCATG AAAGTTGCAG
  481 TGAAGATGCT AAAACCCACG GCCAGATCCA GTGAAAAACA AGCTCTCATG TCTGAACTGA
  541 GGATAATGAC TCACCTGGGG CCACATTTGA ACATCGTAAA CTTGCTGGGA GCCTGCACCA
  601 AGTCAGGCCC CATTTACATC ATCACAGAGT ATTACTTCTA TGGAGATTTG GTCAACTATT
  661 TGCATAAGAA TAGGGATAGC TTCCTGAGCC ACCACCCAGA GAAGCCAAAG AAAGAGCTGG
  721 ATATCTTTGG ACTGAACCCT GCTGATGAAA GCACACGGAG CTATGTTATT TTATCTTTTG
  781 AAAACAATGA TGACTACATG GNCATGAAGC ANGCTGATAC TACACAGTAT GTCCCCATGC
  841 TAGAAAGGAA AGAGGTTTCT AAATATTCCG ACATCCAGAG ATCACTCTAT GATCGTCCNG
  901 CCTCATATAA GAAGAAATCT ATGTTAGANT CANAAGTCAA AAACCTNCTT NCNNNGNNNA
  961 CTCNNANNNN TTACTTTATT GGNNTTGNTG ANCTNNNNCN NNCNNGTNGN CCNANNNNNN
1021 NNNTTTTTGN NTTCNAAAAN NGNGNNNNNN NNNN
//
Primer: beta-gro_rev (Pr0512)
Region: beta-globin pA, insert (FL) 3'
Sequence file: RDB15465_B2Cgb.seq check
>D04855B3_B2Cg_1_ beta-gro_rev_B09_06_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN NTTGCCCCCT CNNTATAACA TGAATTTTAC NATAGCGAAA
   61 AAGAAAGAAC AATCAAGGGT CCCCAAACTC ACCCTGAAGT TCTCAGGATC CGATTATCTC
  121 GAGTTACAGG AAGCTGTCTT CCACCAGGTC TGAAGAGTCT ATGCCGATGT CGTCCATCAT
  181 GTCGATGTCT TCAATGGTCT CGTCCTCTCT CTTGATGAAG GTGGAACTGC TGGAACCCGT
  241 CTCAATGGCA CTCTCTTCAG AGGTCTGCGA GCTGTGTCTG TTCCTCTTGC CCAGGTCCTC
  301 CTCCTCAGGG ACAGGGTCAA TGTCAGGCAG AGGAATGATG TAGCCACTGT CAGCGCTCAG
  361 TCTCTGCTCA TCCAGACCAC CCTCCCAGTC CTTCAGCTTG TCTTCCTCGT TTTTGTAGGT
  421 GACACCAATG TATGCATTGT CTGAGTCCAC ACGCATGCGT GCCACAGCAG GATGGTCACT
  481 CTTCAGGAAG TCCAGGTGAA TTTTTTCATA ACTCTTTTTA TATTGTCCAG GCAGCAGATT
  541 CTCCACAATC TCACTCAGGT GGTAAAAGGA GGGTCTCTTC TCCGGCTCAC TGTTCCAGCA
  601 TTTCACCATG ATCTCGTAGA CTTCACTGGT AGCGTGGTCA GGCTTGGCCA TCCGGTACCC
  661 ACTCTTGATC TTATTGNAGA AAGTAGAATC CACCATCATG CCGGGGTAAN GGGTGNCACC
  721 NANGGAAAAG ATCTCCCANA NCANANNGNC NTAAGACCAG ACATCACTCA GTGTGGTGTA
  781 NAGGNTGNCA AANANGCTCT CNNANCNNTC CNCTTCNCGG GCANAAAGGN ANTGNCTCCC
  841 GANNCNTANT TCNAATCANG CNTGANGTCT CTGGNCNTGN CNAANTCNCN GANNNNCNCN
  901 NTTTTTNNTT GNGNNNNNAN NANNNNNCNA GCANCNNNNT NNNGGNGNNN NNNNNTTTTT
961 TNANNNNAAA CNNCNNTNNN NNNGNNNNNN NNNN
//
Primer: PDGFRA_F3 (Pr1185)
Region: insert (FL) mid
Sequence file: RDB15465_B2Cgc.seq check
>D04855B3_B2Cg_1_PDGFRA_F3_F08_17_ABI24.ab1
    1 NNNNNNNNNN NNNNNNNNNN GNNNNNNTTA NNTNNTCNCN GAGTATTACT TCTATGGAGA
   61 TTTGGTCAAC TATTTGNNTA AGAATAGGGA TAGCTTCCTG AGCCACCACC CAGAGAAGCC
  121 AAAGAAAGAG CTGGATATCT TTGGACTGAA CCCTGCTGAT GAAAGCACAC GGAGCTATGT
  181 TATTTTATCT TTTGAAAACA ATGATGACTA CATGGACATG AAGCAGGCTG ATACTACACA
  241 GTATGTCCCC ATGCTAGAAA GGAAAGAGGT TTCTAAATAT TCCGACATCC AGAGATCACT
  301 CTATGATCGT CCAGCCTCAT ATAAGAAGAA ATCTATGTTA GACTCAGAAG TCAAAAACCT
  361 CCTTTCAGGT GATAACTCAG AAGGCCTTAC TTTATTGGAT TTGTTGAGCT TCACCTATCA
  421 AGTTGCCCGA GGAATGGAGT TTTTGGCTTC AAAAAATTGT GTCCACCGTG ATCTGGCTGC
  481 TCGCAACGTC CTCCTGGCAC AAGGAAAAAT TGTGAAGATC TGTGACTTTG GCATGGCCAG
  541 AGACATCATG CATGATTCGA ACTATGTGTC GGGAGGCAGT ACCTTTCTGC CCGTGAAGTG
  601 NATGGCTCCT GAGAGCATCT TTGACAACCT CTACACCACA CTGAGTGATG TCTGGTCTTA
  661 TGGCATTCTG CTCTGGGAGA NCTTTTCCCT TGNTGGCACC NCTTACCCCG GCATGATGGT
  721 GGATTCTACT TTCTACAATA AGATCAAGAG TGGGTACCGG ATGGCCAAGC CTGACCACGC
  781 TACCNGTGAA GTCTACNANA TCATGGTGAA ATGNTGGAAC AGTGANNCGG ANAANANANC
  841 CTCCTTTTAC CNCNNGANNG ANANTGNGNA GAATCTGNTG NNNGNNNNNT ATAAAAANAG
  901 TNATGAAAAA ATTCNCNNNN NNTNNNNGNA NANNGANNNT CCNGNTGNGN NNNNNNTGNN
961 NGNNNNNTCN NANNNGNATA CNTNNNNNNN NNN
//
Primer: SV40pro_ori_F (Pr0731)
Region: SV40 pro_ori, beta-globin pA
Sequence file: RDB15465_B2Cgd.seq check
>D04855B3_B2Cg_1_ SV40pro_ori_F_C09_09_ABI24.ab1
    1 NNNNNNNNNN NNNNCNNNNG CNNCCTCGNC CTCTGNNCTA TTCCNGAAGT AGTGAAGAGG
   61 CTTTTTTGGA GGCCTAGGCT TTTGCAAAAA GCTCCTCGAG GGATCTCCAT AAGAGAAGAG
  121 GGACAGCTAT GACTGGGAGT AGTCAGGAGA GGAGGAAAAA TCTGGCTAGT AAAACATGTA
  181 AGGAAAATTT TAGGGATGTT AAAGAAAAAA ATAACACAAA ACAAAATATA AAAAAAATCT
  241 AACCTCAAGT CAAGGCTTTT CTATGGAATA AGGAATGGAC AGCAGGGGGC TGTTTCATAT
  301 ACTGATGACC TCTTTATAGC CAACCTTTGT TCATGGCAGC CAGCATATGG GCATATGTTG
  361 CCAAACTCTA AACCAAATAC TCATTCTGAT GTTTTAAATG ATTTGCCCTC CCATATGTCC
  421 TTCCGAGTGA GAGACACAAA AAATTCCAAC ACACTATTGC AATGAAAATA AATTTCCTTT
  481 ATTAGCCAGA AGTCAGATGC TCAAGGGGCT TCATGATGTC CCCATAATTT TTGGCAGAGG
  541 GAAAAAGATC TCAGTGGTAT TTGTGAGCCA GGGCATTGGC CACACCAGCC ACCACCTTCT
  601 GATAGGCAGC CTGCACCTGA NGAGTGAATT CTTTGCCAAA ATGATGAGAC AGCACAACAA
  661 CCAGCACGTT GCCCAGGANC TGTANGAAAG AGAAGAANGN ATGAACATGG TTAGCAGANG
  721 GGCCCGGTTT GNANTCNGAN TATTTTATCC TCATCTCNAA CAGTGTATAT CATTGTAACN
  781 NTAAAGAGAA AGGNAGGANG ANGANNAGGG NGTAGTTGNT TCTANNNATN ANAANANTTC
  841 CNCGCCNGCC NNAANTTATA TGCNNAAATA TTCTACCTTA TCATTTNNTT ATNNNNNTTG
  901 NNCTCTAAAA CTGNGCTGNA NNANNNNATN NNATACCNNG ANNGNCNTNN NAAAAAAANN
961 GANNNNNNNA NGNANNNANN NNNNNNNN
//

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

original Ibata, M., Leukemogenic kinase FIP1L1-PDGFRA and a small ubiquitin-like modifier E3 ligase, PIAS1, form a positive cross-talk through their enzymatic activities. Cancer Sci. 108 (2): 200-207 (2017). PMID 27960034. [link to RRC of NBRP]
reference Iwasaki, J., FIP1L1 presence in FIP1L1-RARA or FIP1L1-PDGFRA differentially contributes to the pathogenesis of distinct types of leukemia. Ann. Hematol. 93 (9): 1473-1481 (2014). PMID 24763514.